Group 1 - The core viewpoint emphasizes that CXO is the "core engine" of global pharmaceutical innovation, significantly benefiting from the active domestic innovative drug BD transactions, with representative companies experiencing a year-on-year doubling of their orders on hand [1] - The industry is positioned as a "water seller," where the demand for upstream life science consumables is directly linked to industry prosperity, with the end of the destocking cycle and the recovery of production activities driving a rebound in the industry [1] - The FDA's announcement to gradually eliminate animal testing may greatly accelerate the development of "organoids + organ-on-chip" technologies, with companies already making early preparations [1]